Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BONFIRE: Beta-blockers discontinuation in HFrecovEF
NCT06518694Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carvedilol in heart failure (HF) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite of death or hospitalization for cardiovascular reason at 1 year. Started Feb 2025; status: recruiting.
02
Drugs
carvedilol
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06518694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518694.